中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2009年
11期
1149-1151
,共3页
氯吡格雷%辛伐他汀%冠心痛%短暂脑缺血发作
氯吡格雷%辛伐他汀%冠心痛%短暫腦缺血髮作
록필격뢰%신벌타정%관심통%단잠뇌결혈발작
Clopidogrel%Simvastatin%Coronary artery disease%Transient isehemic attack
目的 探讨氯吡格雷联合辛伐他汀胶囊治疗冠心病合并短暂脑缺血发作(TIA)的临床疗效观察.方法 选择76例冠心病合并TIA患者,随机分成2组.对照组36例,给予肠溶阿司匹林50 mg×2片(晚餐后服),1次/d.治疗组40例,在对照组基础上加用氯吡格雷片25 mg×2片,1次/d,辛伐他汀胶囊10 mg×2粒(睡前服).所有病例服药前均常规检查肝、肾功能,凝血功能及血脂.随访1年,定期监测肝、肾功能,凝血功能及血脂.结果 治疗组与对照组总有效率比较差异有统计学意义[95.0%(38/40)与55.5%(20/36),χ2=6.45,P<0.01].治疗组治疗前后LDL-C[(3.18±1.24)mmol/L与(2.60±1.03)mmol/L,t=2.67,P<0.01]和TC[(5.18±1.24)mmol/L与(4.02±2.18)mmol/L,t=4.91,P<0.01]均显著降低,而TG差异无统计学意义[(1.50±1.02)mmol/L与(1.30±1.03)mmol/L,t=1.02,P>0.05];对照组差异均无统计学意义(t=0.17、0.00、0.52、0.57,P均>0.05).2组治疗后比较差异均无统计学意义(t=1.51、2.55、0.57,P均>0.05).结论 氯吡格雷片联合辛伐他汀胶囊可安全预防TIA发作.
目的 探討氯吡格雷聯閤辛伐他汀膠囊治療冠心病閤併短暫腦缺血髮作(TIA)的臨床療效觀察.方法 選擇76例冠心病閤併TIA患者,隨機分成2組.對照組36例,給予腸溶阿司匹林50 mg×2片(晚餐後服),1次/d.治療組40例,在對照組基礎上加用氯吡格雷片25 mg×2片,1次/d,辛伐他汀膠囊10 mg×2粒(睡前服).所有病例服藥前均常規檢查肝、腎功能,凝血功能及血脂.隨訪1年,定期鑑測肝、腎功能,凝血功能及血脂.結果 治療組與對照組總有效率比較差異有統計學意義[95.0%(38/40)與55.5%(20/36),χ2=6.45,P<0.01].治療組治療前後LDL-C[(3.18±1.24)mmol/L與(2.60±1.03)mmol/L,t=2.67,P<0.01]和TC[(5.18±1.24)mmol/L與(4.02±2.18)mmol/L,t=4.91,P<0.01]均顯著降低,而TG差異無統計學意義[(1.50±1.02)mmol/L與(1.30±1.03)mmol/L,t=1.02,P>0.05];對照組差異均無統計學意義(t=0.17、0.00、0.52、0.57,P均>0.05).2組治療後比較差異均無統計學意義(t=1.51、2.55、0.57,P均>0.05).結論 氯吡格雷片聯閤辛伐他汀膠囊可安全預防TIA髮作.
목적 탐토록필격뢰연합신벌타정효낭치료관심병합병단잠뇌결혈발작(TIA)적림상료효관찰.방법 선택76례관심병합병TIA환자,수궤분성2조.대조조36례,급여장용아사필림50 mg×2편(만찬후복),1차/d.치료조40례,재대조조기출상가용록필격뢰편25 mg×2편,1차/d,신벌타정효낭10 mg×2립(수전복).소유병례복약전균상규검사간、신공능,응혈공능급혈지.수방1년,정기감측간、신공능,응혈공능급혈지.결과 치료조여대조조총유효솔비교차이유통계학의의[95.0%(38/40)여55.5%(20/36),χ2=6.45,P<0.01].치료조치료전후LDL-C[(3.18±1.24)mmol/L여(2.60±1.03)mmol/L,t=2.67,P<0.01]화TC[(5.18±1.24)mmol/L여(4.02±2.18)mmol/L,t=4.91,P<0.01]균현저강저,이TG차이무통계학의의[(1.50±1.02)mmol/L여(1.30±1.03)mmol/L,t=1.02,P>0.05];대조조차이균무통계학의의(t=0.17、0.00、0.52、0.57,P균>0.05).2조치료후비교차이균무통계학의의(t=1.51、2.55、0.57,P균>0.05).결론 록필격뢰편연합신벌타정효낭가안전예방TIA발작.
Objective To observe the clinical effect of combination of clopidogrel and simvastatin on coro-nary heart disease and transient ischemic attack(TIA). Methods 76 patients with coronary heart disease and TIA were randomly divided into test group (n=40) and control group (n=36). The control group was treated with en-teric-coated aspirin 50 mg×2 every night after supper, and the test group was treated with clopidogrel 25 mg×2 and simvastatin 10 mg×2 every night before sleep. Liver and kidney function, blood coagulation function and blood lipids were measured before treatment and after. 1 year followed-up. Results The effective rate was 95.0% (38/40) in test group and 55.5% (20/36) in control group(χ2=6.45,P<0.01). LDL-C was (3.18±1.24) mmol/L and (2.60±1.03)mmol/L(t=2.67,P<0.01),TC was(5.18±1.24) mmol/L and (4.02±2.18) mmol/L(t= 4.91, P<0.01),TG was (1.50±1.02) mmol/L and (1.30±1.03) mmol/L(t=1.02, P>0.05), respectively in test group before and after treatment. However, there was no statistical difference in LDL-C, TC and TG (t=0.17, 0.00,0.52,0.57,P>0.05 for each) in control group. The two groups showed no difference after treatment (t= 1.51,2.55,0.57, P>0.05 for each). Conclusions Glopidogrel combined with simvastatin capsules is safe in pre-vention of TIA attack.
